β-Blocker Use and Mortality in COPD Patients After Myocardial Infarction: A Swedish Nationwide Observational Study.
(2015) In Journal of the American Heart Association 4(4). p.001611-001611- Abstract
- Patients with myocardial infarction (MI) and concomitant chronic obstructive pulmonary disease (COPD) constitute a high-risk group with increased mortality. β-Blocker therapy has been shown to reduce mortality, prevent arrhythmias, and delay heart failure development after an MI in broad populations. However, the effect of β-blockers in COPD patients is less well established and they may also be less treated due to fear of adverse reactions. We investigated β-blocker prescription at discharge in patients with COPD after MI.
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/5345124
- author
- Andell, Pontus LU ; Erlinge, David LU ; Smith, Gustav LU ; Sundström, Johan ; Lindahl, Bertil ; James, Stefan and Koul, Sasha LU
- organization
- publishing date
- 2015
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Journal of the American Heart Association
- volume
- 4
- issue
- 4
- pages
- 001611 - 001611
- publisher
- Wiley-Blackwell
- external identifiers
-
- pmid:25854796
- wos:000354137300015
- pmid:25854796
- scopus:85012249441
- ISSN
- 2047-9980
- DOI
- 10.1161/JAHA.114.001611
- language
- English
- LU publication?
- yes
- id
- 1e476851-d59f-40d5-b8e2-1110c3162ed4 (old id 5345124)
- alternative location
- http://www.ncbi.nlm.nih.gov/pubmed/25854796?dopt=Abstract
- date added to LUP
- 2016-04-01 15:02:17
- date last changed
- 2022-03-22 03:14:26
@article{1e476851-d59f-40d5-b8e2-1110c3162ed4, abstract = {{Patients with myocardial infarction (MI) and concomitant chronic obstructive pulmonary disease (COPD) constitute a high-risk group with increased mortality. β-Blocker therapy has been shown to reduce mortality, prevent arrhythmias, and delay heart failure development after an MI in broad populations. However, the effect of β-blockers in COPD patients is less well established and they may also be less treated due to fear of adverse reactions. We investigated β-blocker prescription at discharge in patients with COPD after MI.}}, author = {{Andell, Pontus and Erlinge, David and Smith, Gustav and Sundström, Johan and Lindahl, Bertil and James, Stefan and Koul, Sasha}}, issn = {{2047-9980}}, language = {{eng}}, number = {{4}}, pages = {{001611--001611}}, publisher = {{Wiley-Blackwell}}, series = {{Journal of the American Heart Association}}, title = {{β-Blocker Use and Mortality in COPD Patients After Myocardial Infarction: A Swedish Nationwide Observational Study.}}, url = {{https://lup.lub.lu.se/search/files/4308627/8234211}}, doi = {{10.1161/JAHA.114.001611}}, volume = {{4}}, year = {{2015}}, }